Periprosthetic joint infections (PJI), caused by methicillin-resistant Staphylococcus 19 aureus (MRSA), is the major cause of total hip arthroplasty (THA) failures. Traditionally, 20 MRSA is treated with vancomycin, administrated intravenously or applied directly onto infected 21 tissue. The effect of direct (as opposed to systemic) vancomycin treatment on bone formation 22 and remodelling is largely unknown. The minimal inhibitory concentration (MIC) of 23 vancomycin was determined by adding 200 µl of different concentrations (1 -20 µg/ml) to 24 actively growing cultures of S. aureus Xen 31 (methicillin-resistant) and S. aureus Xen 36 25 (methicillin-sensitive), respectively, and recording changes in optical density over 24 h. Bone 26 marrow-derived and proximal femur-derived mesenchymal stem cells (bmMSCs and pfMSCs) 27
INTRODUCTION 42
The three major load bearing joints in the human body are the ankle, knee and hip (1). The 43 human hip joint has a complex anatomical structure and is responsible for carrying the weight of 44 the upper body. During daily activity, the hip joint may experience loading forces up to 7 times 45 the body weight of the individual, generating immense mechanical pressure which is most likely 46 the main cause for osteoarthritis (OA) in this joint (2). OA effects more than 25% of elderly 47 people and is therefore a major cause of disability in this population group (3, 4) . 48 Currently the only treatment available for severe hip OA is total hip arthroplasty (THA) (5).
49
A metal prosthesis is inserted into the proximal region of the femur, replacing the proximal 50 femur head and neck (6). Although THA is considered the most successful orthopaedic 51 procedure of the past 120 years, and although advances in the field have significantly improved 52 the risk profile associated with this procedure over the past five decades, complications still do 53 occur (7-9). Periprosthetic joint infection (PJI) is the main cause for THA revision surgeries and 54 is defined as bacterial contamination of the joint prosthesis and infection of the adjacent tissue 55 (10). Most, if not all, PJI are caused by bacteria capable of forming biofilms (5). Many strains 56 of these bacteria are resistant to a number of antibiotics (11), and treating PJI is therefore 57 extremely difficult. The most common bacterial infections after THA are Gram-positive cocci.
58
Staphylococcus aureus was isolated in 38% of PJI cases. Fifty-three percent of the strains were 59 resistant to methicillin (12).
60
Failed treatment of PJI with conventional antibiotic regimes places an immense burden on 61 medical professionals. Conventional treatments include intravenous administration of antibiotics 62 for a maximum of 2 weeks, while aggressive treatment includes removal of the infected 63 prosthesis and flushing of the infected joint (one-step revision surgery), followed by another 12 64 weeks on antibiotics. Once the infection has been cleared, a new prosthesis is inserted (13). In 65 4 severe cases a surgeon can opt for a two-step revision surgery. This entails initial removal of the 66 infected prosthesis and insertion of an antibiotic-augmented cement spacer, followed by the 67 implantation of a new prosthesis once the bacterial infection has been eradicated (13, 14) . Both 68 one-step and two-step revision surgeries can result in prolonged immobility, hospitalization and 69 morbidity. The cost of treatment of a single episode of PJI can escalate to USD 50,000 or more 70 (9). The increase in antibiotic resistance among hospital-acquired infections like PJI has also 71 increased the risk of failing to successfully treat PJI (15, 16) . It is therefore clear that PJI presents 72 a major challenge from both a health-care and economic perspective (17).
73
Methicillin-resistant Staphylococcus infections are usually treated with vancomycin (18).
74
Vancomycin is either administered intravenously or directly to the infected site, by means of with increased glucocorticoid sensitivity and a reduced osteoblastic differentiation potential in 83 culture. In vivo, pfMSCs reside in the exact area of bone tissue that is in contact with the THA 84 prosthesis, and is therefore likely to participate in osseo-integration of the prosthesis.
85
Consequently, these cells can serve as a relevant in vitro model to assess the effects of directly 86 applied vancomycin on the MSC populations residing in the bone tissue, which could affect the 87 success of THA revision surgeries. In the present study we evaluate the effects on increasing 88 doses of vancomycin in the viability and osteoblastic differentiation of cultured rat bmMSCs and 89 pfMSCs. Brain Heart infusion (BHI) broth, cultured at 37℃, were streaked onto BHI agar and incubated 108 for 24 h at 37℃. A single colony was inoculated into BHI broth and incubated for 18 h at 37℃.
109
Overnight cultures of the two strains were each adjusted to an OD of 0.1 (600 nm). Different 
120
Isolation of bmMSCs and pfMSCs was performed as described by Jacobs and co-workers 121 (25). Femora were surgically removed and cleaned from muscle tissue using sterile gauze. were washed with PBS, fixed for 5 min at 25℃ with 70% (v/v) ethanol and rinsed twice with 169 sterile water. BmMSCs were stained for 2 to 4 hours, after which the excess stain was removed, 170 and cells washed three times with sterile water, once with sterile PBS and an additional three 171 times with sterile water. Bound stain was extracted using 10% (w/v) cetylpyridinium chloride 172 (CPC) dissolved in 10 mM Na 2 HPO 4 (pH 7.0) and quantified spectrophotometrically at 562 nm.
173
PfMSCs were stained overnight with ARS and washed, as described for bmMSC. Since pfMSCs 174 have reduced osteogenic potential, staining was quantified using image analysis. Images were 175 captured using an Olympus CKX41 microscope (CKX41, CachN 10x0.25 PhP objective), fitted 176 with a Canon EOS 600D camera at 10x magnification. Four random images (one in each 177 quadrant) were taken of each well, resulting in 12 images per treatment since experiments were 178 performed in triplicate. Images were analysed with ImageJ software (version 1.51 J8) and 179 converted into red-green-blue stacks. Analyses were performed in the green channel. A 180 threshold value of T=90 was used to exclude non-specific background staining and remained 181 9 unchanged throughout. The percentage area stained was recorded and the average for the 12 182 images per condition was calculated.
183
Statistical analysis. GraphPad Prism (version 5.01) was used for all statistical analyses and 184 data were expressed as average ±SD. One-way ANOVA and Dunnett's post hoc test were used 185 to analyse the data. When P < 0.05, the difference was considered to be statistically significant 186 and indicated with an *. when the PJI has been successfully eradicated.
198
Based on micro-broth dilution assays, the MIC of vancomycin against S. aureus Xen 31 199 (MRSA) was 5 µg/ml and 1 µg/ml against Xen 36, suggesting that S. aureus Xen 31 has reduced 200 susceptibility for vancomycin (27, 28) .
201
Crystal violet stained all cells (dead and alive), while the MTT conversion assay detected Based on ARS staining, bmMSCs were fully differentiated after 7 days of treatment with 206 OM, while pfMSCs formed individual mineralized nodules after 21 days of OM treatment.
207
Mineralization in bmMSCs increased slightly, but not significantly, when treated with 4 x MIC 208 vancomycin (Fig. 3A) . In contrast, pfMSCs treated with vancomycin showed significantly 209 reduced mineralization, compared to OM-treated cells (Fig. 3B) . shown that pfMSCs are more sensitive to glucocorticoids than bmMSCs.
216
Our findings are of particular relevance for THA, as pfMSCs reside in the area directly 217 involved in THA (6). Our results suggest that direct administration of vancomycin to an infected 218 hip joint may not have a detrimental effect on the viability of the MSC population residing in the 219 affected bone tissue and may, therefore, spare the surrounding bone tissue, or at least preserve 220 the capacity for tissue regeneration. The mild anti-osteogenic effects of vancomycin in 221 differentiating pfMSCs may cause local short-term loss of bone mineral density at vancomycin-222 treated sites. However, we hypothesize that the absence of cytotoxicity of vancomycin on 223 undifferentiated pfMSCs may result in the population of pfMSCs surrounding the affected area 224 remaining intact, which will contribute to repair of the bone tissue and successful 225 osseointegration of the prosthesis upon cessation of vancomycin treatment. 
